These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 606425)
1. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease. Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425 [TBL] [Abstract][Full Text] [Related]
2. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422 [TBL] [Abstract][Full Text] [Related]
3. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409 [TBL] [Abstract][Full Text] [Related]
4. Bone disease in children with chronic renal failure: therapy with 1alpha-hydroxyvitamin D3. Postlethwaite RJ; Houston IB Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():117s-124s. PubMed ID: 304772 [TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424 [TBL] [Abstract][Full Text] [Related]
6. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]
7. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125 [TBL] [Abstract][Full Text] [Related]
11. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961 [TBL] [Abstract][Full Text] [Related]
13. 1-alpha-hydroxycholecalciferol for renal osteodystrophy. Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease. Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370 [TBL] [Abstract][Full Text] [Related]
15. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3. Peacock M; Aaron JE; Walker GS; Davison AM Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428 [No Abstract] [Full Text] [Related]
16. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium. Winney RJ; Bone JM; Anderson TJ; Robson JS Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593 [No Abstract] [Full Text] [Related]
17. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484 [No Abstract] [Full Text] [Related]
18. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833 [TBL] [Abstract][Full Text] [Related]
19. Biological activity of endogenous and exogenous calcitonin in patients with osteitis fibrosa and chronic renal failure. Cundy T; Heynen G; Paton S; Ledingham JG; Russell RG; Oliver DO; Kanis JA Proc Eur Dial Transplant Assoc; 1978; 15():524-31. PubMed ID: 740683 [TBL] [Abstract][Full Text] [Related]
20. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy. Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]